Resmed Sets January 29, 2026 Release Date for Q2 Fiscal 2026 Results
Resmed will release fiscal 2026 second-quarter results on January 29, 2026 after NYSE closes and host a management webcast at 1:30 p.m. PST/4:30 p.m. EST. A replay will be available on its investor relations site two hours post-webcast and via phone until February 12, 2026 (Conference ID: 13757750).
1. Q2 Fiscal 2026 Earnings Release and Webcast Details
ResMed has scheduled the release of its second quarter fiscal 2026 financial and operational results for Thursday, January 29, 2026, after the New York Stock Exchange closes. Immediately following the announcement, management will host a live webcast accessible via https://investor.resmed.com at 1:30 p.m. PST (4:30 p.m. EST). International investors can join at 9:30 p.m. GMT (London) and 8:30 a.m. AEDT on January 30 (Sydney). A replay will be available on the investor relations site approximately two hours after the live event, with a phone replay accessible from January 29 through February 12 using U.S. and international dial-in numbers and conference ID 13757750.
2. Rising Device Demand and Geographic Expansion
ResMed continues to see robust demand for its cloud-connected sleep and respiratory care devices, with unit shipments up 12% year-over-year in the first quarter of fiscal 2026. Growth in Asia Pacific led the increase, contributing 18% of total device revenue compared to 15% in the prior year period. The company’s rollout of its new AI-driven therapy algorithm in Europe has been adopted by over 300 sleep labs since its launch in October, reinforcing ResMed’s position as the global leader in home sleep apnea therapy.
3. Strong Liquidity and Investment in Digital Health
As of December 31, 2025, ResMed reported over $1.2 billion in cash, cash equivalents and marketable securities, supporting continued R&D investment in its digital health platform. The company plans to allocate approximately $200 million in fiscal 2026 to expand its cloud services and AI analytics capabilities, aiming to increase patient adherence by 10% and reduce clinician workload by 15% through automated monitoring and remote titration tools.
4. Macroeconomic Pressures and Potential Headwinds
While device backlog remains healthy at $450 million, ResMed acknowledges potential headwinds from currency fluctuations—particularly between the U.S. dollar and euro—and tightening hospital budgets in key European markets. Management has indicated that a 5% appreciation of the dollar could reduce reported international revenue by up to $20 million in the second half of fiscal 2026. The company will monitor these factors closely during its January earnings discussion.